

1       **Breadth of concomitant immune responses underpinning viral clearance**  
2       **and patient recovery in a non-severe case of COVID-19**

3  
4  
5  
6  
7  
8       Irani Thevarajan<sup>1,2#</sup>, Thi HO Nguyen<sup>3#</sup>, Marios Koutsakos<sup>3</sup>, Julian Druce<sup>4</sup>, Leon Caly<sup>4</sup>,  
9       Carolien E van de Sandt<sup>3,5</sup>, Xiaoxiao Jia<sup>3</sup>, Suellen Nicholson<sup>4</sup>, Mike Catton<sup>4</sup>,  
10       Benjamin Cowie<sup>1,2</sup>, Steven YC Tong<sup>1,2,6</sup>, Sharon R Lewin<sup>2,3,7</sup> and  
11       Katherine Kedzierska<sup>3\*</sup>

12  
13  
14  
15       **Affiliations**

16  
17       <sup>1</sup>Victorian Infectious Diseases Service, The Royal Melbourne Hospital at the Peter  
18       Doherty Institute for Infection and Immunity, Melbourne 3000, Victoria, Australia.

19       <sup>2</sup>Doherty Department, The University of Melbourne at The Peter Doherty Institute for  
20       Infection and Immunity, Melbourne 3000, Victoria, Australia.

21       <sup>3</sup>Department of Microbiology and Immunology, The University of Melbourne, at the  
22       Peter Doherty Institute for Infection and Immunity, Parkville 3010, Victoria,  
23       Australia.

24       <sup>4</sup>Victorian Infectious Diseases Reference Laboratory, The Royal Melbourne Hospital  
25       at The Peter Doherty Institute for Infection and Immunity, Melbourne 3000, Victoria,  
26       Australia.

27       <sup>5</sup>Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory,  
28       Amsterdam UMC, University of Amsterdam, 1066CX Amsterdam, Netherlands

29       <sup>6</sup>Menzies School of Health Research, Charles Darwin University, Darwin, Australia.

30       <sup>7</sup>Department of Infectious Diseases, Alfred Hospital and Monash University,  
31       Melbourne, 3010, Victoria, Australia

32  
33       \*Correspondence: [kkedz@unimelb.edu.au](mailto:kkedz@unimelb.edu.au); #authors contributed equally.

34  
35  
36  
37  
38  
39       **Running title:** COVID-19 and cellular immunity

45 **We report the kinetics of the immune response in relation to clinical and**  
46 **virological features of a patient with mild-to-moderate coronavirus disease-19**  
47 **(COVID-19) requiring hospitalisation. Increased antibody-secreting cells,**  
48 **follicular T-helper cells, activated CD4<sup>+</sup> and CD8<sup>+</sup> T-cells and IgM/IgG SARS-**  
49 **CoV-2-binding antibodies were detected in blood, prior to symptomatic**  
50 **recovery. These immunological changes persisted for at least 7 days following**  
51 **full resolution of symptoms, indicating substantial anti-viral immunity in this**  
52 **non-severe COVID-19.**

53  
54

55 On 30/01/2020, a 47-year old woman from Wuhan, Hubei province, China presented  
56 to an emergency department in Melbourne, Australia. Her symptoms commenced 4  
57 days earlier with lethargy, sore throat, dry cough, pleuritic chest pain, mild dyspnoea  
58 and subjective fevers (**Fig.1a**). She had travelled 11 days prior to presentation from  
59 Wuhan via Guangzhou to Australia. She had no contact with the Huanan seafood  
60 market or known COVID-19 cases. She was otherwise healthy, non-smoker, taking  
61 no medications. Clinical examination revealed a temperature of 38.5°C, pulse rate 120  
62 beats/minute, blood pressure 140/80 mmHg, respiratory rate 22 breaths/minute, and  
63 oxygen saturation 98%, while breathing ambient air. Lung auscultation revealed  
64 bibasal rhonchi. At presentation day (d) 4, SARS-CoV-2 was detected by real-time  
65 reverse transcriptase polymerase-chain-reaction (rRT-PCR) from a nasopharyngeal  
66 swab specimen. SARS-CoV-2 was again detected at d5-6 from nasopharyngeal,  
67 sputum and faecal samples, but was undetectable from d7 (**Fig.1a**). Blood C-reactive  
68 protein was elevated at 83.2, with normal lymphocyte counts ( $4.3 \times 10^9/L$  [range  $4.0-$   
69  $12.0 \times 10^9/L$ ]) and normal neutrophil counts ( $6.3 \times 10^9/L$  [range  $2.0-8.0 \times 10^9/L$ ]). No  
70 other respiratory pathogens were detected. Her management was intravenous fluid  
71 rehydration without supplemental oxygenation. No antibiotics, steroids or antiviral  
72 agents were administered. Chest radiography demonstrated bibasal infiltrates at d5,  
73 which cleared on d10 (**Fig.1b**), and she was discharged to home isolation on d11.  
74 Symptoms resolved completely by d13 and she remained well at d20 post-onset of  
75 symptoms. Progressive increase in plasma COVID-19-binding IgM/IgG antibodies,  
76 from d7 until d20 was observed (**Fig.1c**).

77

78 There are currently no data defining immune responses leading to viral clearance and  
79 clinical resolution of COVID-19. We addressed this knowledge gap by analysing the  
80 breadth of immune responses in blood prior to patient recovery. As antibody-secreting  
81 cells (ASCs) are key for the rapid production of antibodies following viral Ebola  
82 infection<sup>1,2</sup>, influenza virus infection and vaccination<sup>2,3</sup>; and activated circulating  
83 follicular T helper (cTfhs) are concomitantly induced following influenza  
84 vaccination<sup>3</sup>, we first determined the frequency of CD3<sup>-</sup>CD19<sup>+</sup>CD27<sup>hi</sup>CD38<sup>hi</sup> ASCs  
85 and CD4<sup>+</sup>CXCR5<sup>+</sup>ICOS<sup>+</sup>PD1<sup>+</sup> cTfh responses at 3 days prior to symptomatic  
86 recovery. ASCs appeared in blood at the time of viral clearance at d7 (1.48%) and  
87 peaked on d8 (6.91%). Emergence of cTfhs occurred concurrently in blood at d7  
88 (1.98%), with the frequency increasing on d8 (3.25%) and d9 (4.46%) (**Fig.2a**). The  
89 peak of both ASCs and cTfhs was markedly higher in the COVID-19 patient than the  
90 baseline levels in healthy controls (average±SD:  $0.61 \pm 0.40\%$  and  
91  $1.83 \pm 0.77\%$ , respectively, n=5). Both ASCs and cTfhs were still prominently present  
92 at convalescence (d20) (4.54% and 7.14%, respectively; **Fig.2a**). Our study provides  
93 evidence on the recruitment of both ASCs and cTfhs in patient's blood whilst still

94 unwell and 3 days prior to resolution of symptoms, indicating their importance in  
95 anti-viral immunity towards SARS-CoV-2.

96  
97 Since co-expression of CD38 and HLA-DR is well defined as the key phenotype of  
98 CD8<sup>+</sup> T-cell activation towards viral infections, we analyzed activation of CD8<sup>+</sup> T-  
99 cells by CD38/HLA-DR co-expression. In accordance with previous reports on Ebola  
100 and influenza<sup>1,4</sup>, CD38<sup>+</sup>HLA-DR<sup>+</sup> co-expression on CD8<sup>+</sup> T-cells rapidly increased  
101 from d7 (3.57%) to d8 (5.32%) and d9 (11.8%), with a decrease at d20 (7.05%)  
102 (**Fig.2b**). Furthermore, the frequency of CD38<sup>+</sup>HLA-DR<sup>+</sup> co-expression on CD8<sup>+</sup> T-  
103 cells in this patient was markedly higher than on CD8<sup>+</sup> T-cells in healthy  
104 individuals (1.47±0.50%, n=5). Similarly, CD38<sup>+</sup>HLA-DR<sup>+</sup> co-expression increased  
105 on CD4<sup>+</sup> T-cells between d7 (0.55%) and d9 (3.33%) in the patient, compared to  
106 healthy donors (0.63±0.28%, n=5), although at lower levels than CD8<sup>+</sup> T-cells.  
107 CD38<sup>+</sup>HLA-DR<sup>+</sup> T cells, especially within CD8<sup>+</sup> T-cells, produced higher amounts  
108 of granzymes A/B and perforin (~34-54% higher) than their parent (CD8<sup>+</sup> or CD4<sup>+</sup>  
109 populations, **Fig.2b**). Thus, the emergence and rapid increase in activated  
110 CD38<sup>+</sup>HLA-DR<sup>+</sup> T-cells, especially CD8<sup>+</sup> T-cells, at d7-9 preceded resolution of  
111 symptoms.

112  
113 We also analysed CD16<sup>+</sup>CD14<sup>+</sup> monocytes, related to immunopathology, and  
114 activated HLA-DR<sup>+</sup>CD3<sup>-</sup>CD56<sup>+</sup> NK cells (**Fig.2c**). We detected reduced frequencies  
115 of CD16<sup>+</sup>CD14<sup>+</sup> monocytes in peripheral blood at d7-9 (1.29%, 0.43%, 1.47%,  
116 respectively), compared to healthy controls (9.03±4.39%, n=5). This might indicate  
117 efflux of CD16<sup>+</sup>CD14<sup>+</sup> monocytes from blood to the site of infection, which remained  
118 low at d20 (2.24%). Low levels of activated HLA-DR<sup>+</sup>CD3<sup>-</sup>CD56<sup>+</sup> NK cells were  
119 found in both the COVID-19 patient and healthy controls.

120  
121 As high levels of pro-inflammatory cytokines/chemokines are predictive of severe  
122 clinical outcomes for influenza<sup>5</sup>, seventeen pro-inflammatory cytokines/chemokines  
123 were quantified in patient's plasma. We found low levels of monocyte  
124 chemoattractant protein-1 (MCP-1; CCL2), important for the recruitment of  
125 monocytes, T-cells and dendritic cells to the site of infection (**Fig.2d**). However, these  
126 MCP-1 levels were similar to healthy donors (22.15±13.81, n=5), patients infected  
127 with influenza A (IAV) and influenza B viruses (IBV) at d7-9 (33.85±30.12, n=5) and  
128 a patient with a known human coronavirus infection HCoV-229e (hCoV, 40.56).  
129 Substantial levels of RANTES (CCL5), involved in homing and migration of  
130 activated T-cells that express CCR5, were also detected in COVID-19 plasma but  
131 these were comparable to healthy donors (p=0.412), IAV/IBV-infected patients  
132 (p=0.310) and a hCoV-patient. Thus, in contrast to severe avian H7N9 disease with  
133 highly elevated IL-6 and IL-8, and intermediate IL-10, MIP-1β, IFN-γ<sup>5</sup>, minimal pro-  
134 inflammatory cytokines/chemokines were found in this patient with CoVID-19, even  
135 while symptomatic at d7-9.

136  
137 Given that interferon-induced transmembrane protein-3 (IFITM3) single nucleotide  
138 polymorphism (SNP)-rs12252-C/C was linked to severe influenza<sup>5,6</sup>, we analysed the  
139 IFITM3- rs12252 SNP in this patient with COVID-19. Interestingly, the patient had  
140 the 'risk' IFITM3-rs12252-C/C variant (**Fig.2e**), associated with clinical compromise  
141 for 2009-pH1N1<sup>6</sup> and severe/fatal avian H7N9 disease<sup>5</sup>. As the relative prevalence of  
142 IFITM3-rs12252-C/C risk variant in a healthy Chinese population is 26.5% (data  
143 from 1,000 genome project)<sup>5</sup>, further investigations of the IFITM3-rs12252-C/C allele

144 in larger cohorts of patients with COVID-19 and its correlation with disease severity  
145 is worth pursuing.

146

147 Collectively, our study provides novel contributions to the understanding of the  
148 breadth of the immune response during a non-severe case of COVID-19. This patient  
149 did not experience complications of respiratory failure, acute respiratory distress  
150 syndrome, did not require supplemental oxygenation and was discharged within a  
151 week of hospitalization, consistent with non-severe but clearly symptomatic disease.  
152 We provide evidence on the recruitment of immune populations (antibody-secreting B  
153 cells, follicular T-cells, activated CD4<sup>+</sup> and CD8<sup>+</sup> T-cells), together with IgM-IgG  
154 SARS-CoV-2-binding antibodies, in patient's blood prior to resolution of clinical  
155 symptoms. We propose that these immune parameters should be characterised in  
156 larger cohorts of patients with COVID-19 with different disease severity to  
157 understand whether they could be used to predict disease outcome and to evaluate  
158 new interventions to minimise severity and/or to inform protective vaccine  
159 candidates. Furthermore, our study indicates that robust multi-factorial immune  
160 responses can be elicited towards the newly-emerged SARS-CoV-2, and similar to the  
161 avian H7N9 disease<sup>7</sup>, early adaptive immune responses might correlate with better  
162 clinical outcomes.

163

164

## 165 **References**

166 1. McElroy, A.K. *et al. Proc Natl Acad Sci USA* **112**, 4719-4724 (2015).

167 2. Ellebedy, A.H. *et al. Nat Immunol* **17**, 1226-1234 (2016).

168 3. Koutsakos, M. *et al. Sci Transl Med* **10** (2018).

169 4. Wang, Z. *et al. Nat Commun* **9**, 824 (2018).

170 5. Wang, Z. *et al. Proc Natl Acad Sci USA* **111**, 769-774 (2014).

171 6. Everitt, A.R. *et al.* **484**, 519-523 (2012).

172 7. Wang, Z. *Nat Commun* **6**: 6833 (2015).

173

174

175 **Fig.1. Time course of clinical presentation and detection of SARS-CoV-2 in a**  
176 **range of clinical specimens and antibodies to SARS-CoV2 in blood. (a)** Timeline  
177 of COVID-19; detection of SARS-CoV-2 virus in sputum, nasopharyngeal aspirates,  
178 faeces but not urine, rectal swab and whole blood. SARS-CoV-2 was quantified by  
179 real-time RT-PCR and the cycle threshold (Ct) is shown for each of the specimen. An  
180 increase in Ct value is consistent with a decrease in viral load. The assay limit of  
181 detection (LOD) threshold is Ct=45. Open circles: undetectable SARS-CoV-2; **(b)**  
182 Radiological improvement from admission to discharge from hospital.  
183 Anteroposterior chest radiographs on d5 (day of admission) and d10 following onset  
184 of symptoms; **(c, d)** Immunofluorescence antibody staining for the detection of IgG  
185 and IgM bound to SARS-CoV-2-infected vero cells using plasma (diluted 1:20)  
186 collected at d7-9 and d20 following onset of symptoms.

187

188 **Fig.2. Emergence of immune responses during non-severe symptomatic COVID-**  
189 **19.** Frequencies of **(a)** CD27<sup>hi</sup>CD38<sup>hi</sup> antibody-secreting cells (ASC; plasmablasts,  
190 gated on CD3<sup>-</sup>CD19<sup>+</sup> lymphocytes) and activated ICOS<sup>+</sup>PD1<sup>+</sup> follicular T helper  
191 (Tfh) cells (gated on CD4<sup>+</sup>CXCR5<sup>+</sup> lymphocytes); **(b)** activated CD38<sup>+</sup>HLA-DR<sup>+</sup>  
192 CD8<sup>+</sup> and CD4<sup>+</sup> T-cells; **(c)** lineage CD14<sup>+</sup>CD16<sup>+</sup> monocytes and activated HLA-DR<sup>+</sup>  
193 NK cells (gated on CD3<sup>-</sup>CD14<sup>-</sup>CD56<sup>+</sup> cells) detected by flow cytometry for blood

194 collected at d7-d9 and d20 following onset of symptoms and in healthy donors  
195 (median with IQ range); **(b)** Histograms and line graphs of granzymes A/B/K/M and  
196 perforin (Prf) staining of parent CD8<sup>+</sup> or CD4<sup>+</sup> T cells and activated CD38<sup>+</sup>HLA-  
197 DR<sup>+</sup>CD8<sup>+</sup>/CD4<sup>+</sup> T-cells are shown (bottom panels). **(d)** Plasma levels of pro-  
198 inflammatory cytokines/chemokines in COVID-19 patient at d7-9, healthy individuals  
199 (n=5, mean±SEM), patient with HCoV-229e and influenza-infected patients (n=5). **(e)**  
200 ‘risk’ IFITM3-rs12252 genotyping for the COVID-19 patient.

201

202

## 203 **Acknowledgments**

204 The authors thank Prof Cameron Simmons for supporting the development of  
205 SETREP-ID, all the SETREP-ID investigators for their support and Australian  
206 Partnership for Preparedness Research for Infectious Disease Emergencies  
207 (APPRISE) for ongoing funding of SETREP-ID. We thank Dr Louise Rowntree for  
208 technical assistance. This work was funded by the Australian National Health and  
209 Medical Research Council (NHMRC) Investigator Grant to KK (#1173871). CES has  
210 received funding from the European Union’s Horizon 2020 research and innovation  
211 programme under the Marie Skłodowska-Curie grant agreement No 792532 and  
212 University of Melbourne McKenzie Fellowship laboratory support. KK is supported  
213 by a NHMRC Senior Research Fellowship Level B (#1102792) and SRL is supported  
214 by an NHMRC Practitioner Fellowship and an NHMRC program grant. SYCT is  
215 supported by a NHMRC Career Development Fellowship (#1145033). XJ is  
216 supported by China Scholarship Council-University of Melbourne joint Scholarship.  
217 The authors wish to acknowledge our public health partners, and VIDRL’s major  
218 funder, the Victorian Department of Health and Human Services without whom this  
219 work would not have been possible, and the clinical and laboratory staff involved in  
220 the care of this patient.

221

222

223

224

## 224 **Online content**

225

## 226 **Author contribution**

227 IT, THON, MK, CES, LC, SN, XJ, JD, MK, BC, SYT, SRL, KK formulated ideas,  
228 designed the study and experiments; THON, MK, CES, LC, SN, XJ, JD performed  
229 experiments; THON, MK, LC, SN, JD analysed the experimental data, KK, IT,  
230 THON, SYT, BC, SRL wrote the manuscript. All authors reviewed the manuscript.

231

## 232 **Competing interests**

233 The authors declare no conflict of interest. SRL’s institution has received funding for  
234 investigator initiated research grants from Gilead Sciences, Merck, Viiv Healthcare  
235 and Leidos. She has received honoraria for participation in advisory boards and  
236 educational activities for Gilead Sciences, Merck, Viiv Healthcare and Abbvie.

237

## 238 **Methods**

### 239 **Study design**

240 The patient was enrolled through the Sentinel Travelers Research Preparedness  
241 Platform for Emerging Infectious Diseases novel coronavirus substudy (SETREP-ID  
242 coV). Sputum, nasopharyngeal aspirates, urine and faecal specimens as well as whole

243 blood in sodium heparin tubes were collected over the duration of illness and 9 days  
244 post discharge for quantitative virology, immunology and assessment of host gene  
245 factors. Human experimental work was conducted according to the Declaration of  
246 Helsinki Principles and according to the Australian National Health and Medical  
247 Research Council Code of Practice. Participants provided written informed consent  
248 prior to the study. The study was approved by the Royal Melbourne Hospital (HREC  
249 Reference number: HREC/17/MH/53 and HREC/15/MonH/64/2016.196) and  
250 University of Melbourne (ID #1442952.1 and #1443389.4) Human Research Ethics  
251 Committees.

252

### 253 **Generation of SARS-CoV-2 cDNA**

254 RNA was extracted from 200 $\mu$ L from patient's swabs (nasopharyngeal, rectal, throat  
255 in VTM), sputum, urine, faeces and whole-blood samples using the QIAamp 96 Virus  
256 QIAcube HT Kit (Qiagen, Hilden, Germany). Reverse transcription was performed  
257 using the BioLine SensiFAST cDNA kit (Bioline, London, United Kingdom). Total  
258 reaction mixture of 20 $\mu$ L contained 10 $\mu$ L of the RNA extract, 4 $\mu$ L of 5x TransAmp  
259 buffer, 1 $\mu$ L of Reverse Transcriptase and 5 $\mu$ L of Nuclease free water. Reactions were  
260 incubated at 25°C for 10 min, 42°C for 15 min, 85°C for 5 min.

261

### 262 **Nested SARS-CoV-2 RT-PCR and Sanger sequencing**

263 A PCR mixture containing 2 $\mu$ L cDNA, 1.6 $\mu$ L of 25 mM MgCl<sub>2</sub>, 4 $\mu$ L of 10x Qiagen Taq  
264 Buffer, 0.4 $\mu$ L of 20mM dNTPs, 0.3 $\mu$ L of Taq polymerase (Qiagen, Hilden, Germany)  
265 and 2 $\mu$ L of 10 $\mu$ M primer pools as described<sup>11</sup>. The first round included the forward  
266 (5'-GGKTGGGAYTAYCCKAARTG-3') and reverse (5'-  
267 GGKTGGGAYTAYCCKAARTG-3') primers. Cycling conditions were 94°C for 10  
268 min, followed by 30 cycles of 94°C for 30s, 48°C for 30s and 72°C for 40s, with a  
269 final extension of 72°C for 10 min. PCR product (2 $\mu$ L) was used in the second round  
270 PCR reaction which included the forward (5'-GGTTGGGACTATCCTAAGTGTGA-  
271 3') and reverse (5'-CCATCATCAGATAGAATCATCAT-3') primers. Cycling  
272 conditions were 94°C for 10min, followed by 40 cycles of 94°C for 30s, 50°C for 30s  
273 and 72°C for 40s, with a final extension of 72°C for 10 min. PCR products had an  
274 expected size of approximately 440bp on a 2% agarose gel. The PCR products were  
275 purified using ExoSAP-IT (Affymetrix, Santa Clara, CA, USA) and sequenced using  
276 an Applied Biosystems SeqStudio Genetic Analyzer (Life Technologies, Carlsbad,  
277 CA, USA) using Big Dye Terminator 3.1 (Life Technologies, Carlsbad, CA, USA)  
278 and Round 2 PCR primers above. SARS-CoV and 229e-CoV cDNA were used as  
279 positive controls.

280

### 281 **Detection of SARS-CoV-2 using TaqMan Real-time RT-PCR E-gene assay**

282 TaqMan RT-PCR assay comprised of 2.5 $\mu$ L cDNA, 10 $\mu$ L Primer Design  
283 PrecisionPLUS qPCR Master Mix 1 $\mu$ M Forward (5'-ACA GGT ACG TTA ATA GTT  
284 AAT AGC GT -3'), 1 $\mu$ M Reverse (5'-ATA TTG CAG CAG TAC GCA CAC A-3')  
285 primers and 0.2 $\mu$ M Probe (5'-FAM-ACA CTA GCC ATC CTT ACT GCG CTT CG-  
286 NFQ-3') targeting the Betacoronavirus E-gene<sup>1</sup>. The real-time RT-PCR assay was  
287 performed on an Applied Biosystems ABI 7500 Fast Real-time PCR machine  
288 (Applied Biosystems, Foster City, CA, USA) with cycling conditions 95°C for 2min,  
289 95°C for 5s, 60°C for 24s. SARS-CoV cDNA (Ct~30) was used as a positive control.

290

### 291 **IFITM3 SNP analysis**

292 PCR was performed on genomic DNA extracted from patient's granulocytes (using  
293 QIAamp DNA Mini Kit, QIAGEN) to amplify the *exon 1* rs12252 region using  
294 forward (5'-GGAAACTGTTGAGAAACCGAA-3') and reverse (5'-  
295 CATACGCACCTTCACGGAGT-3') primers<sup>2</sup>.

296

### 297 **Cytokine analysis**

298 Patient's plasma was diluted 1:4 before measuring cytokine levels (IL-2, IL-4, IL-6,  
299 IL-8, IL-10, IL-12p70, IL-17A, IL-1 $\beta$ , IFN- $\alpha$ , MIP-1 $\alpha$ , MIP-1 $\beta$ , MCP-1,  
300 CD178/FasL, granzyme B, RANTES, TNF, IFN- $\gamma$ ) using the Human CBA Kit (BD  
301 Biosciences, San Jose, California, USA). For RANTES, sera/plasma was also diluted  
302 to 1:50. Healthy donors D6-D10 were of a mean age of 32 (range 22-55 years; 40%  
303 females).

304

### 305 **Whole blood staining and flow cytometry**

306 Fresh whole blood (200 $\mu$ l per stain) was used to measure CD4<sup>+</sup>CXCR5<sup>+</sup>ICOS<sup>+</sup>PD1<sup>+</sup>  
307 follicular T cells (Tfh) and CD3<sup>+</sup>CD19<sup>+</sup>CD27<sup>hi</sup>CD38<sup>hi</sup> antibody-secreting B cell  
308 (ASC; plasmablast) populations as described<sup>3</sup> as well as activated HLA-  
309 DR<sup>+</sup>CD38<sup>+</sup>CD8<sup>+</sup> and HLA-DR<sup>+</sup>CD38<sup>+</sup>CD4<sup>+</sup> T cells, inflammatory CD14<sup>+</sup>CD16<sup>+</sup> and  
310 conventional CD14<sup>+</sup> monocytes, activated HLA-DR<sup>+</sup>CD3<sup>+</sup>CD56<sup>+</sup> NK cells, as per the  
311 specific antibody panels (Supplementary Table 1; gating strategy is presented in  
312 Supplementary Fig.1). After the whole blood was stained for 20 mins at room  
313 temperature (RT) in the dark, samples were lysed with BD FACS Lysing solution,  
314 washed and fixed with 1% PFA. Granzymes/perforin staining (patient d20) was  
315 performed using the eBioscience Foxp3/Transcription Factor Staining Buffer Set after  
316 the lysis step. All the samples were acquired on a LSRII Fortessa (BD). Flow  
317 cytometry data were analyzed using FlowJo v10 software. Healthy donors D1-D5  
318 were of a mean age of 35 (range 24-42 years, 40% females).

319

### 320 **Detection of IgG and IgM antibodies in SARS-CoV-2 -infected vero cells**

321 Immunofluorescence antibody tests for the detection of IgG and IgM were performed  
322 using SARS-CoV-2-infected vero cells that had been washed with PBS and  
323 methanol/acetone fixed onto glass slides. Ten  $\mu$ L of a 1/20 dilution of patient plasma  
324 in PBS from days 7, 8, 9 and 20 were incubated on separate wells for 30 mins at  
325 37°C, then washed in PBS and further incubated with 10 $\mu$ L of FITC-conjugated goat  
326 anti-human IgG and IgM (Euroimmun, Lübeck, Germany) before viewing on a  
327 EUROStar III Plus fluorescent microscope (Euroimmun). Prior to detection of IgM  
328 antibodies, samples were pre-treated with RF-SorboTech (Alere, Rüsselsheim,  
329 Germany) to remove IgG antibodies and rheumatoid factors, which may cause false-  
330 negative and false-positive IgM results, respectively.

331

### 332 **Reference**

- 333 1. Corman, V.M. *et al. Eurosurveillance* **25**, doi: 10.2807/1560-  
334 7917.ES.2020.25.3.2000045 (2020).
- 335 2. Clemens, E.B. *et al. Immunol & Cell Biol* **94**, 367-377 (2016).
- 336 3. Koutsakos, M. *et al. Sci Transl Med* **10** (2018).

337

338

339

### 340 **Data availability**

341 The data that support the findings of this study are available from the corresponding  
342 author upon request. Raw FACS data are shown in the manuscript.

343

344

345 **Supplementary Table 1. Whole blood immunophenotyping and antibody panels**  
346 **used in our immune assays.**

347

348 **Supplementary Figure 1. Flow cytometry gating strategy for immune cell**  
349 **subsets.** Gating panels are shown for **(a)** CD27<sup>hi</sup>CD38<sup>hi</sup> ASCs and activated  
350 ICOS<sup>+</sup>PD1<sup>+</sup> Tfh cells; **(b)** activated CD38<sup>+</sup>HLA-DR<sup>+</sup> CD8<sup>+</sup> and CD4<sup>+</sup> T-cells,  
351 activated HLA-DR<sup>+</sup> NK cells and lineage<sup>-</sup>CD14<sup>+</sup>CD16<sup>+</sup> monocytes; and **(c)**  
352 granzymes (GZM) A/B/K/M and perforin expression on CD8<sup>+</sup>/CD4<sup>+</sup> T-cells and  
353 activated CD38<sup>+</sup>HLA-DR<sup>+</sup> CD8<sup>+</sup>/CD4<sup>+</sup> T-cells.

354






Figure 1. Thevarajan *et al*




Figure 2. Thevarajan *et al*